Altimmune, Inc. (ALT)
Automate Your Wheel Strategy on ALT
With Tiblio's Option Bot, you can configure your own wheel strategy including ALT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ALT
- Rev/Share 0.0002
- Book/Share 2.0757
- PB 2.1776
- Debt/Equity 0.0857
- CurrentRatio 17.1835
- ROIC -0.4354
- MktCap 398922996.0
- FreeCF/Share -0.7455
- PFCF -5.9844
- PE -4.8164
- Debt/Assets 0.0728
- DivYield 0
- ROE -0.5479
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | ALT | Barclays | -- | Overweight | -- | $20 | Jan. 28, 2026 |
| Resumed | ALT | Goldman | -- | Sell | -- | $1 | July 10, 2025 |
| Initiation | ALT | William Blair | -- | Market Perform | -- | -- | Feb. 28, 2025 |
| Initiation | ALT | Stifel | -- | Buy | -- | $18 | Jan. 8, 2025 |
News
Altimmune to Participate in the Citizens Life Sciences Conference
Published: April 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
GAITHERSBURG, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that members of the Company's management team will participate in a fireside chat at the Citizens Life Sciences Conference. Details are as follows:
Read More
Altimmune Q4 Earnings Review: The Big News Is The MASH With Obesity Data Readout Due Q2
Published: February 28, 2025 by: Seeking Alpha
Sentiment: Positive
Altimmune's pemvidutide shows promise in treating MASH with obesity, potentially positioning it as a first-in-class drug targeting both liver health and weight loss. Despite past volatility, ALT stock has stabilized, with recent data showing significant weight loss at higher doses, sparking renewed investor interest. Altimmune's Q4 2024 earnings reveal a net loss of $23.2m, with $131.9m in cash, highlighting the company's ongoing financial challenges and reliance on future clinical success.
Read More
Altimmune, Inc. (ALT) Q4 2024 Earnings Call Transcript
Published: February 27, 2025 by: Seeking Alpha
Sentiment: Neutral
Altimmune, Inc. (NASDAQ:ALT ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Lee Roth - President, Burns McClellan, Investor Relations Advisors Vipin Garg - Chief Executive Officer Scott Harris - Chief Medical Officer Greg Weaver - Chief Financial Officer Scot Roberts - Chief Scientific Officer Conference Call Participants Yasmeen Rahimi - Piper Sandler Annabel Samimy - Stifel Liisa Bayko - Evercore William Wood - B. Riley Securities Jonathan Wolleben - Citizens JMP Patrick Trucchio - H.C.
Read More
Altimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
Top-line data from Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) to be reported in Q2 2025 Investigational New Drug (IND) applications in two additional indications have received FDA clearance, with Phase 2 trials to commence mid-2025 Company to hold virtual R&D Day on March 13, 2025. Program will include KOL presentations on pemvidutide development in obesity, MASH and additional indications Two pharmaceutical industry veterans added to Company Board of Directors Cash, cash equivalents and short-term investments of $131.9 million on December 31, 2024 Webcast to be held today, February 27, 2025, at 8:30 a.m.
Read More
Altimmune's Catalytic Moment In 2025: Pemvidutide's Phase 2b Trial In MASH
Published: February 18, 2025 by: Seeking Alpha
Sentiment: Positive
Altimmune is a single-molecule company currently trading at a $0.5 billion market cap with a favorable risk-reward profile. The company's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH (metabolic dysfunction-associated steatohepatitis). Pemvidutide has successfully completed a Phase 1 trial for a related liver disease but has yet to demonstrate efficacy in the target indication of MASH.
Read More
About Altimmune, Inc. (ALT)
- IPO Date 2017-05-26
- Website https://altimmune.com
- Industry Biotechnology
- CEO Jerome Benedict Durso
- Employees 59